The Effect of Autologous Serum Therapy in Chronic Spontaneous Urticaria Depends on Autologous Serum Skin Test Positivity.
Chronic spontaneous urticaria (CSU) is a common distressing disease caused mainly by autoreactive mechanisms. Autologous serum therapy (AST) has been tried for treatment of many autoimmune diseases including chronic urticaria. We assessed the effect of AST in autologous serum skin test (ASST)-positive and ASST-negative CSU patients. The study included 40 patients clinically diagnosed as CSU. Twenty ASST-positive patients and 20 ASST-negative patients received AST for 8 weeks. Urticarial activity was assessed at baseline, 4th week, 9th week, and at the 12th week by the weekly urticarial activity score (UAS-7) according to the EAACI/GA2LEN/EDF/WAO guidelines. Antihistamine pill burden was assessed at every visit. The mean UAS-7 was significantly decreased in ASST-positive patients after AST at the 4th and 9th weeks (P < 0.05) but the decrease was non-significant at the 12th week. In ASST-negative patients, the decrease in the mean UAS-7 was significant only at the 4th week. Ten percent of the ASST-positive patients showed complete remission after AST and no patients in either group showed relapse after treatment. There was no difference in the mean UAS-7 between the two groups at baseline but significant difference was observed at 4th, 9th and 12th week. The difference in antihistamine pill burden was also significant at the 12th week (P < 0.001). We concluded that AST is more efficient in decreasing disease severity and antihistamine use in ASST-positive CSU patients than in ASST-negative patients.